Therapie der chronisch thromboembolischen pulmonalen Hypertonie

Zusammenfassung

Die chronisch thromboembolische pulmonale Hypertonie (CTEPH) ist eine wichtige und oft gut behandelbare Form der pulmonalen Hypertonie. Es stehen aktuell 3 Therapiemodalitäten zur Verfügung: die pulmonale Endarteriektomie, die pulmonale Ballonangioplastie und die gezielte medikamentöse Behandlung. Das therapeutische Konzept hängt maßgeblich von der Lokalisation der zugrunde liegenden pulmonalarteriellen fibrösen Obstruktionen ab. Die pulmonale Endarteriektomie ist der Goldstandard in der Behandlung der CTEPH. Für inoperable Patienten stehen mittlerweile 2 zugelassene Substanzen (Riociguat und Treprostinil) zur Verfügung. Daneben wird bei Vorhandensein entsprechender Zielgebiete die interventionelle Therapie empfohlen. Evaluation und Behandlung von CTEPH-Patienten sollte in entsprechend erfahrenen Zentren erfolgen.

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is an important form of pulmonary hypertension. Nowadays, three treatment modalities are available: pulmonary endarterectomy, pulmonary balloon angioplasty, and targeted medical treatment. The therapeutic concept depends mainly on the exact localization of the underlying pulmonary arterial obstructions. Pulmonary endarterectomy is the gold standard in the treatment of CTEPH. For inoperable patients, two approved drugs (riociguat and treprostinil) are available. In addition, interventional therapy is recommended if there are appropriate target lesions. Evaluation and treatment of CTEPH patients in experienced centers is mandatory.

Schlüsselwörter

chronisch thromboembolische pulmonale Hypertonie - pulmonale Endarteriektomie - pulmonale Ballonangioplastie

Keywords

chronic thromboembolic pulmonary hypertension - pulmonary endarterectomy - balloon pulmonary angioplasty

• Literatur

• 1 Humbert M, Kovacs G, Hoeper MM. et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2022;
• 2 Guerin L, Couturaud F, Parent F. et al. Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary embolism. Thromb Haemost 2014; 112: 598-605
• 3 Klok FA, Dzikowska-Diduch O, Kostrubiec M. et al. Derivation of a clinical prediction score for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. J Thromb Haemost 2016; 14: 121-128
• 4 Narechania S, Renapurkar R, Heresi GA. Mimickers of chronic thromboembolic pulmonary hypertension on imaging tests: a review. Pulm Circ 2020; 10: 2045894019882620
• 5 Lasch F, Karch A, Koch A. et al. Comparison of MRI and VQ-SPECT as a screening test for patients with suspected CTEPH: CHANGE-MRI study design and rationale. Front Cardiovasc Med 2020; 7: 51
• 6 Humbert MS, Simonneau G, Pittrow D. et al. Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2022; 41: 716-721
• 7 Pengo V, Denas G, Zoppellaro G. et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018; 132: 1365-1371
• 8 Nagel C, Prange F, Guth S. et al. Exercise training improves exercise capacity and quality of life in patients with inoperable or residual chronic thromboembolic pulmonary hypertension. PLoS One 2012; 7: e41603
• 9 Nagel C, Nasereddin M, Benjamin N. et al. Supervised exercise training in patients with chronic thromboembolic pulmonary hypertension as early follow-up treatment after pulmonary endarterectomy: a prospective cohort study. Respiration 2020; 99: 577-588
• 10 Kim NH, Delcroix M, Jais X. et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2019; 53: 1801915
• 11 Lankeit M, Krieg V, Hobohm L. et al. Pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2017;
• 12 Delcroix M, Lang I, Pepke-Zaba J. et al. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. Circulation 2016; 133: 859-871
• 13 Quadery SR, Swift AJ, Billings CG. et al. The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension. Eur Respir J 2018; 52: 1800589
• 14 Ghofrani HA, D’Armini AM, Grimminger F. et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013; 369: 319-329
• 15 Sadushi-Kolici R, Jansa P, Kopec G. et al. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial. Lancet Respir Med 2019; 7: 239-248
• 16 Guth S, D’Armini AM, Delcroix M. et al. Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry. ERJ Open Res 2021; 7: 00850-2020
• 17 Brenot P, Jais X, Taniguchi Y. et al. French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Eur Respir J 2019; 53: 1802095
• 18 Kataoka M, Inami T, Hayashida K. et al. Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 2012; 5: 756-762
• 19 Mahmud E, Behnamfar O, Ang L. et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Interv Cardiol Clin 2018; 7: 103-117
• 20 Mizoguchi H, Ogawa A, Munemasa M. et al. Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 2012; 5: 748-755
• 21 Olsson KM, Wiedenroth CB, Kamp JC. et al. Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. Eur Respir J 2017; 49: 1602409
• 22 Inami T, Kataoka M, Yanagisawa R. et al. Long-term outcomes after percutaneous transluminal pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Circulation 2016; 134: 2030-2032
• 23 Jaïs X, Brenot P, Bouvaist H. et al. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study. Lancet Respir Med 2022; 10: 961-971
• 24 Cannon JE, Su L, Kiely DG. et al. Dynamic risk stratification of patient long-term outcome after pulmonary endarterectomy: results From the UK National Cohort. Circulation 2016; 133: 1761-1771
• 25 Wiedenroth CB, Liebetrau C, Breithecker A. et al. Combined pulmonary endarterectomy and balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2016; 35: 591-596
• 26 Mayer E, Jenkins D, Lindner J. et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg 2011; 141: 702-710